Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion – Head and neck cancer

4782 - A window of opportunity trial of preoperative nivolumab with or without tadalafil in squamous cell carcinoma of the head and neck (SCCHN): safety, clinical, and correlative outcomes

Date

28 Sep 2019

Session

Poster Discussion – Head and neck cancer

Presenters

Adam Luginbuhl

Citation

Annals of Oncology (2019) 30 (suppl_5): v449-v474. 10.1093/annonc/mdz252

Authors

A.J. Luginbuhl1, J.M. Johnson2, L. Harshyne2, M. Tuluc3, S. Mardekian3, B.E. Leiby4, J.M. Curry1, D.M. Cognetti1, Y. Kim5, K. Mannion5, U. Rodeck6, A. Argiris2

Author affiliations

  • 1 Department Of Otolaryngology–head & Neck Surgery, Thomas Jefferson University, 19107 - Philadelphia/US
  • 2 Medical Oncology, Thomas Jefferson University, 19107 - Philadelphia/US
  • 3 Pathology, Thomas Jefferson University, 19107 - Philadelphia/US
  • 4 Pharmacology And Experimental Therapeutics, Kimmel Cancer Center-Thomas Jefferson University, 19107 - Philadelphia/US
  • 5 Dept Of Otolaryngology Head And Neck Surgery, Vanderbilt University, 37232 - Nashville/US
  • 6 Dermatology And Cutaneous Biology, Thomas Jefferson University, 19107 - Philadelphia/US

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4782

Background

Tadalafil is a phosphodiesterase-5 inhibitor was found to decrease MDSC, Treg, arginase and iNOS expression with an increase in cytotoxic effector T cells. In order to improve on the clinical efficacy of PD-1 blockade platform, we designed a window of opportunity trial to test the immunological and therapeutic effects of nivolumab and tadalafil combination.

Methods

We conducted an investigator-initiated, two-arm multi-institutional window of opportunity randomized trial in patients with SCCHN of any stage, who were candidates for complete surgical resection (NCT03238365). Subjects in the two cohorts received nivolumab 240 mg intravenously on day 1 and 15 followed by surgery on day 28. Subjects in the combination cohort received tadalafil 10 mg p.o. once daily for 4 weeks. Patients were stratified to HPV status. Imaging, blood and tumor were obtained pretreatment and post treatment and used for immunological correlatives. The primary endpoint was correlative analysis of immune cell polarization. We present results with complete study accrual.

Results

Of 47 randomized patients, 21 had HPV + tumors. 45/47 patients completed the treatment regimen. Grade 3 serious adverse event (SAEs) occurred in 18% of pts. No related AE’s resulted in delay of surgery. Preliminary evaluation of pathologic treatment effect (TE) was assessed on post treatment specimens showing that 25% of pts demonstrated no treatment effect (TE), 25% had 1-20% TE, 41% had 21-99%TE and 9% had CR. Patients receiving tadalafil amplified intratumoral transcript levels consistent with enhanced myeloid infiltration and T cell activation. This was associated with changes in cytokine levels in patients sera consistent with altered myeloid phenotypes.

Conclusions

Nivolumab +/- tadalafil demonstrated a range of treatment responses with 50% of pts having a pathologic TE > 21% in 4 weeks. In the context of PD-1 blockade, tadalafil enhanced T lymphocyte and myeloid cell infiltration. The mechanisms underlying this shift warrant further investigation.

Clinical trial identification

NCT03238365.

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Bristol-Myers Squibb.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.